Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Inovio Pharmaceuticals's quarterly market cap
declined
from Sep. 2025 (€108.22 Mil) to Dec. 2025 (€97.29 Mil) but then
increased
from Dec. 2025 (€97.29 Mil) to Mar. 2026 (€100.47 Mil).
Inovio Pharmaceuticals's annual market cap
declined
from Dec. 2023 (€126.09 Mil) to Dec. 2024 (€64.26 Mil) but then
increased
from Dec. 2024 (€64.26 Mil) to Dec. 2025 (€97.29 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Inovio Pharmaceuticals's Enterprise Value for Today is €58.71 Mil.
Inovio Pharmaceuticals (FRA:GBM) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:GBM vs NRXS, FBIO, PYPD: Market Cap Comparison
For the Biotechnology subindustry, Inovio Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inovio Pharmaceuticals Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inovio Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Inovio Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Inovio Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Inovio Pharmaceuticals (FRA:GBM) has a Market Cap of €84.17 Mil as of Jul. 15, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Inovio Pharmaceuticals and its competitors. According to the industry distribution chart, Inovio Pharmaceuticals ranks #751 out of 1423 companies in the Biotechnology industry, placing it in the top 52.8%.
Is Inovio Pharmaceuticals' Market Cap too high?
Inovio Pharmaceuticals' current Market Cap is €84.17 Mil. Based on the distribution chart, Inovio Pharmaceuticals ranks #751 out of 1423 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Inovio Pharmaceuticals has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Inovio Pharmaceuticals' Market Cap compare to NRXS and FBIO?
According to the Biotechnology industry distribution chart, Inovio Pharmaceuticals ranks #751 out of 1423 companies for Market Cap. This places Inovio Pharmaceuticals in the lower half of its industry. The industry median Market Cap is 114.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 114.24, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Inovio Pharmaceuticals and its competitors. For the Biotechnology industry, the median Market Cap is 114.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Inovio Pharmaceuticals's current Market Cap is €84.17 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inovio Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Inovio Pharmaceuticals (FRA:GBM) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.19, compared to a current price of €1.00 — trading 425.3% above its estimated fair value. The current Market Cap is €84.17 Mil. Inovio Pharmaceuticals' overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Inovio Pharmaceuticals (FRA:GBM), the current Market Cap is €84.17 Mil as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Inovio Pharmaceuticals (FRA:GBM) Overvalued in 2026?
Based on GuruFocus' analysis, Inovio Pharmaceuticals stock appears to be overvalued.
The current stock price of €1.00 is trading 425.3% above its estimated GF Value™ of €0.19.
GuruFocus considers Inovio Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for FRA:GBM:
Market Cap: €84.17 Mil
GF Value™: €0.19 vs. price of €1.00 (425.3% above fair value)
No single metric tells the full story. See the FRA:GBM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
43GF Score
Get the complete analysis for FRA:GBM
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GBM has been successfully added to your 
